Concepedia

Author

Robert J. Fram

Dana-Farber Cancer InstituteORCID

Also Known As

Fram, Robert J., R Fram, R J Fram, R. Fram, R. J. Fram, R.J. Fram, ROBERT FRAM, Rand K. Fram, Robert Fram, Robert J Fram

109

Publications

2.2K

Citations

30

H-Index

96

Concepts

All Affiliations

Dana-Farber Cancer InstituteTakeda (United States)University of Massachusetts Chan Medical SchoolMillennium Engineering and Integration (United States)Harvard University
RJ

About

Robert J. Fram is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

27

927

2

Natural Sciences

8

8

220

3

Health Sciences

7

7

167

4

Biochemistry

3

3

129

5

Public Health

2

2

72

Robert J. Fram

×

46

Publications

1.8K

Citations

27

H-Index

YearCitations

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.

Barbara A. Conley, Merrill J. Egorin, Nancy Tait,

PubMed

1998

155

A clinically relevant SCID-hu in vivo model of human multiple myeloma

Pierfrancesco Tassone, Paola Neri, Daniel R. Carrasco,

Blood

2005

114

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Adès, Larisa Girshova, Vadim Doronin,

Blood Advances

2022

112

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study

Donna Glover, Alan Lipton, Alan Keller,

Cancer

1994

106

DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin.

Robert J. Fram, D Kufe

PubMed

1982

81

Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage.

Robert J. Fram, Paul S. Cusick, John M. Wilson,

Molecular Pharmacology

1985

74

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway

Kenji Ishitsuka, Teru Hideshima, Makoto Hamasaki,

Oncogene

2005

68

Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.

Robert J. Fram, Bruce A. Woda, John M. Wilson,

PubMed

1990

63

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Casey Cunningham, Leonard J. Appleman, David P. Ryan,

Clinical Cancer Research

2005

51

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Scot Ebbinghaus, Eric H. Rubin, Evan M. Hersh,

Clinical Cancer Research

2005

49

Page 1